Literature DB >> 10965656

[Seven cases of brain metastasis from papillary thyroid carcinoma].

K Ikekubo1, M Hino, H Ito, K Hirao, M Ueshima, T Tanaka, H Kobayashi, T Ishihara, H Kurahachi.   

Abstract

Brain metastases from differentiated thyroid carcinoma are extremely rare and carry a poor prognosis. We describe here clinical details of 7 cases of brain metastases from papillary thyroid carcinoma. Of 153 patients with metastases from differentiated thyroid carcinoma (papillary in 123, follicular in 30) treated at our institution between 1981 and 1999, 7 patients (4.6%) had brain metastases. Histologically, the primary tumor was papillary carcinoma in all 7 cases. Four were males and 3 were females. The median age at first diagnosis of distant metastases was 63 yr (range, 47-76 yr). Of these patients, one had brain metastases only and six had metastases to the lungs as well. Five of these patients were treated with 131I. Three of these 5 patients had marked uptake in the metastases (131I positive) on post-therapy 131I scans and another 2 patients had no significant activity (131I negative) in both pulmonary and brain metastatic lesions. One of 3 patients with 131I positive lesions had intense activity in the brain tumor, but no uptake in multiple pulmonary metastatic tumors. In a patient with 131I positive brain metastases, the tumors progressed rapidly after 131I therapy. In another one patient, acute hemorrhage of the tumor occurred four days after 131I therapy, requiring surgical removal. Loner case of 131I negative 2 patients was treated with radiosurgery (gamma-knife) and complete reduction in tumor volume was observed. On the other hand, one of 2 patients receiving no 131I therapy had radiosurgery (x-knife) and remaining one received conventional external radiation and chemotherapy for small solitary brain and pulmonary metastatic tumors. These therapeutic interventions were useful in both cases. The mean length of survival after the development of brain metastases in the five patients who died of the disease was 30 months. One patient treated with x-knife has been alive at 21 months and another one who has 131I uptake in the brain tumor without uptake in lung lesions has been alive 15 months after diagnosis of brain metastasis. These results indicate that it is important to detect brain metastasis by imaging techniques and Tg measurements and give treatment as early as possible since the brain is the third most common distant metastatic site and the prognosis is poor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10965656

Source DB:  PubMed          Journal:  Kaku Igaku        ISSN: 0022-7854


  5 in total

1.  Metastases in the sphenoidal sinus in a patient with papillary thyroid cancer.

Authors:  Sonia Argibay Vázquez; Carmen Lancha Hernández; Angel Martínez Muñiz
Journal:  Clin Transl Oncol       Date:  2005-08       Impact factor: 3.405

2.  Long-term survival in a patient with brain metastases of papillary thyroid carcinoma.

Authors:  Daniela Guelho; Cristina Ribeiro; Miguel Melo; Francisco Carrilho
Journal:  BMJ Case Rep       Date:  2016-03-09

3.  Rationale for therapeutic decision-making in locally advanced and metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer, starting from a clinical case.

Authors:  Cristina Alina Silaghi; Oana Stãnoiu-Pînzariu; Horaţiu Silaghi; Doina Piciu; Carmen Emanuela Georgescu
Journal:  Arch Clin Cases       Date:  2021-12-29

4.  Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes.

Authors:  Cristiane J Gomes-Lima; Di Wu; Sarika N Rao; Sree Punukollu; Rama Hritani; Alexander Zeymo; Hala Deeb; Mihriye Mete; Edward F Aulisi; Douglas Van Nostrand; Jacqueline Jonklaas; Leonard Wartofsky; Kenneth D Burman
Journal:  J Endocr Soc       Date:  2018-11-21

5.  Brain Metastases From Differentiated Thyroid Carcinoma: A Retrospective Study of 22 Patients.

Authors:  Tong Wu; Zan Jiao; Yixuan Li; Jin Peng; Fan Yao; Weichao Chen; Ankui Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-16       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.